Please login to the form below

Not currently logged in
Email:
Password:

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Affimed rockets on $5bn-plus Roche immuno-oncology deal

ALL). A third drug from the platform –CD33/CD3 T cell engager AMV564 – has been licensed to US biotech Amphivena and is in phase I for the treatment of acute myeloid

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Taking a lean and careful approach Taking a lean and careful approach

    Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,

  • Deal Watch June 2016 Deal Watch June 2016

    Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding

  • Pharma deals during December 2014 Pharma deals during December 2014

    platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Pharma deals during February 2014 Pharma deals during February 2014

    CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics